NCT01392911View on ClinicalTrials.gov

Safety, Tolerability, Extended Early Bactericidal Activity and PK of Higher Doses Rifampicin in Adults With Pulmonary TB

PHASE2CompletedINTERVENTIONAL
Enrollment

128

Participants

Timeline

Start Date

June 30, 2011

Primary Completion Date

July 31, 2018

Study Completion Date

November 30, 2018

Conditions
Pulmonary Tuberculosis (TB)
Interventions
DRUG

Rifampicin

High dose rifampicin

Trial Locations (2)

7531

TASK Applied Science, Bellville

7700

University of Cape Town Lung Institute, Mowbray

All Listed Sponsors
collaborator

European and Developing Countries Clinical Trials Partnership (EDCTP)

OTHER_GOV

collaborator

Department of Clinical Pharmacy, University Medical Centre St Radboud, The Netherlands.

OTHER

collaborator

University Centre for Chronic Diseases Dekkerswald, Groesbeek, NL

UNKNOWN

lead

Radboud University Medical Center

OTHER

NCT01392911 - Safety, Tolerability, Extended Early Bactericidal Activity and PK of Higher Doses Rifampicin in Adults With Pulmonary TB | Biotech Hunter | Biotech Hunter